Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.71 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691549 | 0.87 | MAPK14 (0.72) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL3376470 | 0.87 | MAPK14 (0.77) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL13184789 | 0.85 | MAPK14 (0.71) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL12000959 | 0.85 | MAPK14 (0.71) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL15930180 | 0.82 | MAPK14 (0.66) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL13377946 | 0.82 | MAPK14 (0.70) | MAPK14SCN9ALCKCYP2C9CYP2C19 | |
| SCHEMBL20263149 | 0.82 | MAPK14 (0.66) | MAPK14RIPK2SCN9ALCKCYP2C9 | |
| SCHEMBL20209829 | 0.81 | MAPK14 (0.48) | MAPK14RIPK2SCN9AFGFR1SRC | |
| SCHEMBL3520425 | 0.79 | ALDH1A1 (0.69) | MAPK14CYP2C19LMNARAB9ASMN1; SMN2 | |
| SCHEMBL31116973 | 0.79 | ALDH1A1 (0.69) | MAPK14CYP2C19LMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148461-A1 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F12 | MAPK14 202/4885RIPK2 416/4885SCN9A 1671/4885 |
| US-10208068-B2 | Macrocycles as factor XIa inhibitors | TFPI, TFPI2, F12 | MAPK14 264/4885RIPK2 489/4885SCN9A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.